US-based biopharmaceutical company Microbion has enrolled the first patient in its Phase IIa trial of MBN-101 to treat orthopedic implant-related infections.
MBN-101 is the company’s bismuth-thiol class lead drug candidate, which is being developed to combat against difficult to treat infections.
Go deeper with GlobalData
Its anti-bacterial properties render it effective against a wide range of pathogens, including multiple priority pathogens or superbugs.
MBN-101 has also exhibited its ability to eradicate microbial biofilms.
The randomised, placebo-controlled, dose ranging Phase IIa trial will enrol patients with implant-related orthopedic infections.
The trial is intended to assess the safety and efficacy of MBN-101 in improving patient outcomes who are afflicted with orthopedic implant related infections.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPerelman School of Medicine, University of Pennsylvania orthopaedic surgery associate professor orthopaedic trauma division chief and principal investigator of study Dr Samir Mehta said: "When treating difficult infections associated with orthopedic implants, which are increasingly common, physicians urgently need more effective treatments.
"We are eager to evaluate MBN-101 as a potentially important new treatment for patients with orthopedic infections, as it represents a new therapeutic approach that benefits from recent advances in our understanding of bacteria."
MBN-101 has been awarded the qualified infectious disease product (QIDP) designation by the US Food and Drug Administration (FDA) indicated for post-surgical orthopedic implant infections, and was also granted Fast Track status for this indication by the FDA last year.
